8:30 am - Registration

9 am - Introductory Comments
Wade Harper, PhD, HMS Cell Bio

9:10 am - Keynote 1
Ray Deshaies, PhD, Amgen
*The coming era of multispecific molecular drugs*

10 am - Session 1: *Regulation of protein degradation*
Lee Zou, PhD, MGH Cancer Center
*Session Chair*
Tom Rapoport, PhD, HHMI, HMS Cell Bio
*Mechanism of ER-associated protein degradation (ERAD)*

**Coffee Break**
Susan Shao, PhD, HMS Cell Bio
*Mechanisms of ribosome-associated quality control*
Sun Hur, PhD, BCH, HMS BCMP
*E3 ligase RIPLET in innate immunity*
Ben Ebert, MD, PhD DFCI, HMS BCMP
*Therapeutic modulation of the CRL4-CRBN ubiquitin ligase*

12:20 - 1:30 pm - Lunch on your own

1:30 pm - Session 2: *Degradomics and targeting the ubiquitin system*
Randy King, PhD, HMS Cell Bio
*Session Chair*
Ray Deshaies, PhD
Raymond Deshaies, Ph.D., is senior vice president, Global Research. Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute. He has published over 150 papers on various subjects including discoveries of Sec61 translocon, cullin–RING ubiquitin ligases, and proteolysis-targeting chimeric molecules (Protacs).

In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Biosciences.

Deshaies holds a bachelor’s degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences, and American Academy of Arts and Sciences.

Jay Bradner, MD
James (Jay) Bradner, M.D., joined Novartis on January 1, 2016 and became President of the Novartis Institutes for BioMedical Research (NIBR) on March 1, 2016. He is a member of the Executive Committee of Novartis.

Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States from 2005 through 2015. Dr. Bradner is a co-founder of five biotechnology companies and has authored more than 200 scientific publications and 30 US patent applications.

Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women’s Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.